Latest:
Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
By Anita T. Shaffer
Latest:
Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor Types
OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.
By Ann Partridge, MD, MPH
Latest:
Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology Clinic
Ann Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.
By Arta Monjazeb, MD
Latest:
Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma
Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.
By Audrey Andrews
Latest:
ASH 2010: Data Support Escalated BEACOPP as Superior Method of Tumor Control in Early Unfavorable Hodgkin Lymphoma
In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.
By Barbara Daly, PhD, RN, FAAN
Latest:
Preparing Nurses for Advanced Practice in Oncology and Palliative Care
Barbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.
By Barbara J. Gitlitz, MD, Stephen V. Liu, MD
Latest:
USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice
Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.
By Christin Melton
Latest:
Home Sales: It%u2019s A Buyer%u2019s Market
This year, most Americans have seen the value of their home drop faster than a lead weight. If you purchased your home in the last 10 years, during the housing boom, you will likely find that it is worth less today than what you paid for it%u2014and in some cases less than what you still owe.
By Christina T. Loguidice
Latest:
Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical Approach
Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.
By Daniel C. Cho, MD
Latest:
Sequencing VEGFR-Targeted and mTOR-Targeted Therapy in Advanced Renal Cell Carcinoma
With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.